Answers are grounded in this paper and cite their sources.
Shows improved metabolic outcomes in mice pretreated with human milk oligosaccharides, suggesting therapeutic potential.
. Male ICR mice were pretreated with SL (25 or 75 mg/kg) prior to STZ administration. STZ challenge markedly increased serum glucose levels, disrupted hepatic enzyme profiles, impaired protein metabolism, and induced liver apoptosis and inflammation. SL pretreatment significantly improved glucose homeostasis, normalized liver enzyme activities and serum protein indices, reduced hepatic caspase-3 activation, and suppressed pro-inflammatory cytokine expression in the liver and skeletal muscle. Mechanistically, SL restored AMPK-Akt-mTOR signaling in metabolic tissues. Collectively, these data demonstrate that SL confers systemic metabolic protection against STZ-induced diabetes, highlighting its potential as a therapeutic or preventive agent targeting inflammatory and metabolic pathways.
No takes yet. Share an insight, caveat, or question.
Phan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: